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the “change from baseline” of the IPSS score (p0.1464). The same applies to the
analyses at 3 and 6 months where the p-values were 0.1156 and 0.1723 respectively.
Concerning the 2 dimensions of SF12 score, we observe an improvement but there
is no statistical difference between the 2 treatment groups (physical dimension,
p0.6954 and 0.9878 at 6 weeks and 6 months respectively; mental dimension,
p0.5139 and 0.9044 at 6 weeks and 6 months respectively). CONCLUSIONS: We
observed an improvement in the IPSS and SF12 scores from 6 weeks. This improve-
ment was not significantly different between the 2 treatment groups. Under actual
conditions of use, the various medical treatments gave similar improvements.
PIH13
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OBJECTIVES: Impact studies evaluate the benefit of vaccination on specific out-
come measures in real live conditions. Those studies collect raw data that do not
allow for making general assessments because sometimes the numbers are too
low. Modelling techniques can fine-tune the raw data into more harmonised
( parametric) data presentation. But what do we learn after this transformation?
METHODS: We collected data over 5 years on hospitalisation due to rotavirus in-
fection in children  5 years old before (2y) and after (3y) the introduction of
vaccination in 9 Belgian hospitals. We split the annual data by age-group of 2 to 3
months when  1-year-old and by year thereafter over the period of the epidemic
spread. We harmonised the data using Riskview software in Excel
®
. The hypothe-
ses tested are that the age-groups most vulnerable to the disease have the largest
epidemic spread (highest number of weeks/y of cases reported) and that the less
vulnerable age-groups have their spread during the peak weeks of the most vul-
nerable ones. The latter should indicate a way of disease transmission between
age-groups that could be confirmed with vaccination. RESULTS: Pre-vaccination
data analysis indicates the widest spread of the disease in the age-group of 9 to 11
months (39 wks/52) and the smallest ones in the very young (33 wks/52) and the
oldest ones (8 wks/52). The data confirms the spread of the disease in the less
vulnerable ones (younger and older ones) occurring during the peak moment of the
season of the most vulnerable ones. Post-vaccination analysis shows the same
pattern of dependency between the age-groups. CONCLUSIONS: Preferential
spread of the disease starting from the 9 to 11 months old age-group to younger and
older ones can be deduced from the data analysis. This could give an explanation
for the annual self-limiting spread of rotavirus disease.
PIH14
RATES AND PREDICTORS OF CHLAMYDIA RE-SCREENING AMONG PRIVATELY
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OBJECTIVES: Repeat chlamydial infections are known to cause tubal scarring, ec-
topic pregnancy and infertility. CDC has recommended rescreening 3 months after
a diagnosis of Chlamydia. The objective was to examine the rate and predictors of
retesting within 3-6 months among patients (15-50 years) diagnosed with Chla-
mydia in privately insured population. METHODS: A commercial insurance data-
base was used to extract patients with Chlamydia (ICD-9-CM codes: 99.5X, 78.88,
79.88, 79.98, 99.41) in year 2007-2009. The date of first Chlamydia diagnosis was
used as the index date. Patients were required to have private health insurance
6 months before and after the index date. We also defined the re-screening service
for Chlamydia by using the CPT codes: 87270, 87320, 87110, 87491, 87492, and 87801
within 3-6 months after the index date. Logistic regression model was used to
identify factors affecting the likelihood of Chlamydia retesting. RESULTS: Among
2585 persons diagnosed with Chlamydia, the distribution across age group was
59.8% (15-25 years), 31.2% (26-40 years), and 9.0% (41-50). The majority were women
(74.2%). Only 9.8% (252/2585) patients were rescreened within 3-6 months. The rate
of re-screening in 2007, 2008 and 2009 was 9.1%, 10.3%, and 9.2%, respectively. The
rescreened individuals were more likely to be: women but not pregnant (OR2.36,
95% CI: 1.59-3.50), pregnant women (OR3.01, 95% CI: 1.76-5.13), compared to men;
and age 15-25 years old (OR2.65, 95% CI1.33-5.30), compared to the age group
40-50 years. The insurance type, region or index year were not significantly asso-
ciated with retesting. CONCLUSIONS: Low re-screening rates persisted among per-
sons diagnosed with Chlamydia in the private sector. Since insurance type and
region show no impact on retesting, low rates may relate to system-wide problems.
To improve rescreening rate, policy makers should urgently consider policy op-
tions including rescreening of all Chlamydia cases for effective control of the dis-
ease.
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OBJECTIVES: Herpes zoster (HZ), which is caused by reactivation of the varicella-
zoster-virus (VZV), and its main complication postherpetic neuralgia (PHN) are not
notifiable in Germany. HZ disease burden data are needed to i) estimate the eco-
nomic impact of the disease ii) monitor the impact of routine childhood varicella
vaccination on HZ-epidemiology, and iii) guide decision-making related to the de-
velopment of a possible HZ-vaccination recommendation. METHODS: We as-
sessed annual HZ-incidence for 2007/2008 for all ages in person-years (PY). For
HZ-outpatient incidence we utilized the Association of Statutory Health Insurance
Physicians (ASHIP) database containing nationwide routine accounting data. An-
nual number of HZ-associated deaths and HZ-inpatients were identified by using
the Federal Health Monitoring System (FHM). PHN-incidence and loss of quality-
adjusted life years (QALYs) were modelled by multiplying upper and lower limit
estimates for proportion of HZ-cases developing PHN and HZ-related QALY-loss
with number of identified HZ-outpatients. RESULTS: We identified an annual av-
erage of 480,927 HZ-outpatient cases, resulting in a HZ-incidence of 5.9/1,000 PY. Of
these, 63.5% were 50 years and over. On average, 16,964 HZ-associated inpatients
(84% 50 years) and 71 deaths (all 50 years) were reported annually. HZ-outpa-
tient incidence increased by age from 2.71/1,000 PY in people 0-14 years to 13.18/
1,000 PY in people aged 90. In terms of outpatient (6.94 vs. 4.81/1,000 PY) and
inpatient (0.24 vs. 0.17/1,000 PY) HZ-incidence and mortality (0.13 vs. 0.04/100,000
PY) females were significantly more affected. We estimated that PHN-incidence
ranged between 0.18 and 1.33/1,000 PY and that HZ-outpatients lost between 4,807
and 27,179 QALYs annually.CONCLUSIONS:HZ poses a considerable burden on the
health care system in Germany, especially in the elderly. A health economic model
for Germany will be developed, and follow-up assessments of epidemiological and
economic HZ-related disease burden will be performed to monitor the impact of
VZV-vaccinations in Germany.
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OBJECTIVES: The aging of the Taiwan population is one of the major public health
issues we face now. The physical difference between young and elderly is signifi-
cant and may induce many drug-related problems. Once geriatrics suffered from
adverse drug reactions, they may need for intensive care and increased the finan-
cial burden. Consequently, medication safety is one of the critical issues for elderly.
Analyzing the adverse drug reactions in geriatric patients and announce to health-
care related professionals to prevent the incidences. METHODS: The data was
claimed form Reporting System of Adverse Drug Reaction of a regional teaching
hospital from Jan 2010 to Dec 2010. RESULTS: Four hundred forty cases were ex-
tracted from computer-assisted system. Of 228 geriatrics (51.82%) was enrolled
with mean age 77.03  0.74 years old, including 116 female and 112 male. The
reason to cause adverse drug reaction is Type 1 (58.26 %), undesired pharmacology
reaction, and others were Type 2 (41.74%). The most strategies to management
adverse effects were to cease medicine and give another relievable drug (29.82%),
only cease medicine (28.51%) and varied to alternative medicine (21.93%). Analyz-
ing the severity of event, 55.26% is moderate (needing therapy or inducing to admit
hospital ).CONCLUSIONS:Over half events happened on elderly and make patients
need more advance therapy, and undesired pharmacology effects, which are pre-
ventable, are the most reasons. For this reason, health care related professionals
should pay more attention and monitor closely to enhance medication safety when
a drug was prescribed to elderly.
Individual’s Health – Cost Studies
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OBJECTIVES: To describe the burden of illness associated with neural tube defects
(NTDs) in Germany from a payer perspective. METHODS: Retrospective data of
patients with Spina Bifida (SB) and Encephalocele were analyzed using 2006-2009
German health insurance fund data (Techniker Krankenkasse). Patients were iden-
tified using ICD10 codes, data assessed included outpatient and inpatient care,
rehabilitation, remedies and medical aids, and use of pharmacotherapy. The anal-
ysis was stratified by age group to provide a lifetime burden estimate and was
compared to standardized health care expenditures from the German Risk Com-
pensation Scheme (RSA) to obtain an indicator of incremental burden due to NTD.
RESULTS: Overall, 4,173 patients were identified, 47.2% of whom were male and
95% had SB. 19.6% and 17.5% patients had an additional diagnosis of depression
and incontinence respectively. Costs of patients with SB and Encephalocele were
substantially higher than general population in all age strata. The difference was
highest for patients10 years old (€10,775 vs. €2,360 for1 year olds, €8,398 vs. €833
for 2-5, and €10,686 vs. €863 for 6-10) and smallest for 41-50 (€2,596 vs. €1,101) and
71 group (€5,256 vs. €4,389). Inpatient care contributed 78% of total cost for pa-
tients 0-1, whereas remedies and medical aids accounted for 60% of total cost for
patients 2-5 and 6-10. Among sub-groups, costs of patients with Spina Bifida and
Hydrocephalus were highest, especially in the first 10 years of life. CONCLUSIONS:
The burden of NTD in Germany is substantial and continues throughout the patient
life in terms of the level of health care expenditures and relative to overall popu-
lation. Efforts should be devoted to improving prevention of NTDs and providing
appropriate support for patients, parents, and caregivers, especially in early years.
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BACKGROUND: Seasonal epidemics with rotavirus gastroenteritis (RVGE) and re-
spiratory syncytial virus (RSV) represent a significant burden on paediatric clinical
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services. For the majority of UK children, length of stay (LOS) in hospital is brief and
rehydration alone is sufficient. More complex support is sometimes needed in
children with co-morbidities. OBJECTIVES: To compare the hospital burden (LOS
and cost), of children with RVGE and RSV alone, and vulnerable children with
co-morbidities. METHODS: Hospital data were obtained from the CHKS database
between April 1, 2001 and March 31, 2008, where patients, aged 5 years, were
admitted with a primary diagnosis of RVGE or RSV. Patients were categorised into
three groups. G1: a primary diagnosis of RVGE/RSV, G2: controls with a primary
diagnosis of eczema, G3: vulnerable children with a readmission for RVGE/RSV
following a prior admission, within 30 days, with a primary diagnosis of type 1
diabetes (T1D), cystic fibrosis, cancer, or epilepsy. RESULTS: A total of 102,270
patients were selected, group one n101,784 (mean age 0.2 years, LOS 1.9 days, cost
£595), group two n17,420, (mean age 1.1, LOS 1.7, cost £590), and group three
n486, (mean age 1.1, LOS 9.9, cost £3,477). Non-parametric tests showed that
mean age, and hospital LOS were significantly different between groups 1 and 2
(p0.001), while mean age, LOS, and cost were significantly different between
groups 1 and 3 (p0.001), and groups 2 and 3 (p0.001). When adjusted for age,
regression analysis showed that LOS was 5.2 times higher, and cost was 5.8 times
higher in group 3 than group 1. CONCLUSIONS: This study shows that vulnerable
children readmitted to hospital with RVGE/RSV, incur a greater LOS, and subse-
quent cost, compared to other groups. Universal rotavirus vaccination would sub-
stantially benefit vulnerable children through direct or indirect protection and
reduce the healthcare resource use resulting from hospital readmissions.
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OBJECTIVES: Estimating the costs associated with outbreaks and the prevention of
secondary cases of invasive meningococcal disease (IMD) is needed to understand
the true economic burden of IMD. We aimed to review the costs associated with
IMD outbreaks that occur globally. METHODS: Literature searches were conducted
in MEDLINE and EMBASE using medical subject headings and key words, such as
costs, outbreaks, and IMD. Studies were included if they reported the costs associ-
ated with IMD outbreaks and were written in English, French or Spanish. All costs
were converted to USD 2010. RESULTS: A total of 1672 citations were screened and
323 were potentially relevant. Nine studies fulfilled the inclusion criteria and in-
cluded IMD outbreaks with cost data from the US (n4), England, Canada, Guinea,
Burkina Faso and Australia (n1 each) between November 1992 and November
2006. Three outbreaks occurred among high school children, one among boys aged
3-6 years, another among individuals aged 18 years, and two occurred among all
ages. The majority were due to serogroup C (n7/9). The median number of in-
fected per outbreak was 8 (range: 3-2435). The attack rate ranged from 2 per
100,000 to 187 per 100,000, the hospitalization rate from 55.6% to 100%, and the
death rate from 0% to 26%. Containment strategies ranged from targeting all mem-
bers of the school where the outbreak occurred to targeting all students in the
community. The overall average cost per containment was $2,368,135 (USD 2010)
ranging from an average of $296,821 for small containment strategies (n3) to
$3,403,792 for large containment strategies (n6). CONCLUSIONS: IMG outbreaks
were associated with substantial costs. While numerous reports on outbreaks were
identified, few reported on the containment costs. More research in this area is
warranted, particularly to understand the economic value of new vaccines given
that the purpose of vaccination is to prevent potential outbreaks.
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OBJECTIVES: Endometriosis (the presence of endometrial-like tissue outside the
uterus) affects 10% of women of reproductive age and is associated with dysmen-
orrhoea, pain at ovulation, dyspareunia, abnormal bleeding, chronic pelvic pain,
fatigue, and infertility. This study aimed to calculate costs and health-related qual-
ity of life of women with endometriosis-associated symptoms treated in referral
centres. METHODS: A prospective, international, multi-centre questionnaire-
based survey measured costs and health-related quality of life in ambulatory care
and in 12 tertiary care centres in ten countries. The study enrolled women with a
diagnosis of endometriosis and with at least one centre-specific contact related to
endometriosis-associated symptoms in 2008. The main outcome measures in-
cluded health care costs, costs of productivity loss, total costs and quality-adjusted
life years. Predictors of costs were identified using regression analysis. RESULTS:
Data analysis of 909 women (63% response rate) demonstrated that the average
annual total cost per woman was €9,579 (95% CI €8,559-€10,599). Costs of produc-
tivity loss of €6298 per woman were double the health care costs (€3113 per
woman). Health care costs were mainly due to surgery (29%), monitoring tests (19%)
and hospitalization (18%). The cost of medication accounted for 10% of health care
costs. At a prevalence rate of 7%, the annual burden of endometriosis-associated
symptoms ranged from €0.8 billion in Denmark to €50 billion in the United States.
Endometriosis-associated symptoms generated 0.809 quality-adjusted life years
per woman. Decreased quality of life was the most important predictor of direct
health care and total costs. Costs were greater with increasing severity of endome-
triosis, presence of pelvic pain, presence of infertility, and higher number of years
since diagnosis. CONCLUSIONS: The economic burden associated with endome-
triosis is high and is similar to other chronic diseases (diabetes, Crohn’s disease,
rheumatoid arthritis). It arises predominantly from productivity loss, and is pre-
dicted by decreased quality of life.
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OBJECTIVES: To evaluate cost–effectiveness of pneumococcal vaccination with
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D vaccine
(PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV-13) and
no vaccination in The Kingdom of Saudi Arabia (KSA). METHODS: A steady state
model with a one-year time horizon was developed to project the impact of vacci-
nation on the incidence of pneumococcal and non-typeable Haemophilus Influenzae
(NTHi) infections in children aged 0-10 years. Data sources: Pneumococcal serotype
distribution is based on 176 invasive S. pneumoniae isolates collected in KSA hospi-
tals in 2005 to 2008. IPD, hospitalised pneumonia and acute otitis media (AOM)
disease incidence rates were based on a study from 12 hospitals in KSA, data from
Turkey and benchmarks with other countries. Vaccines coverage rates for IPD of
79.3 % and 83.9% for PHiD-CV and PCV-13, payer perspective, no herd protection
and a (31) vaccination schedule was assumed. RESULTS: PHiD-CV and PCV-13 are
projected to prevent more cases of invasive disease (724; 749 respectively) and
equal number of pneumonia hospitalizations (510; 510 respectively) compared to
no vaccination. PHiD-CV and PCV-13 are projected to prevent additional myringot-
omies (4783; 2365 respectively) and GP visits due to AOM (170,936; 84,518 respec-
tively) compared to no vaccination strategy. Vaccinating a birth cohort with
PHiD-CV or PCV-13 is expected to generate 8,966; 8,888 more QALYs compared to no
vaccination. At vaccine steady state cost-savings related to disease burden reduc-
tion are $14.1M and $7.6M for PHiD-CV and PCV-13 respectively compared with no
vaccination. Sensitivity analyses indicate that incidence rate of IPD has the biggest
impact on results. CONCLUSIONS: Incremental cost-effectiveness ratios indicate
that both vaccines are cost effective interventions. PHiD-CV dominates PCV-13
because it has a larger potential QALY gain and larger cost offset.
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OBJECTIVES: A 7-valent pneumococcal conjugate vaccine (PCV7) was launched as
a Category II vaccine requiring out-of-pocket payment in China in 2008. This study
evaluates the potential economic benefits of introducing a public financed City
Immunization Program (CIP) to pay for PCV7 from a payer perspective. METHODS:
A decision-analytic model was populated with local direct cost and seroprevalence
data from case records of 3 hospitals (1 Children’s Hospital; 2 Comprehensive Hos-
pitals) and literature to estimate the clinical and economic impact of no PCV7
vaccination, PCV7 Category II listing, and PCV7 CIP in the city of Shenzhen. Various
sources of data were used to estimate the primary statistics including age-specific
incidence/mortality of invasive pneumococcal disease (IPD), pneumonia and otitis
media, local patient demographics, and PCV7 efficacy from clinical trial data. The
indirect effect on unvaccinated populations was considered by estimating the re-
duction in adult IPD cases following PCV7 programs published overseas, and was
only applied in the CIP scenario where broad vaccine coverage could be achieved. A
discount rate of 5% was applied, and one-way sensitivity analyses were performed
as well. RESULTS: Under the current setting, the Category II vaccine PCV7 is not
cost-effective due to the private market unit price and low penetration rate. How-
ever, vaccination of 154,721 children under 2 years old from a public financed CIP in
Shenzhen would prevent 18 IPD, 5887 hospitalized pneumonia, 20020 outpatient
pneumonia, and 10669 otitis media cases if indirect effects are included, compared
to no vaccination program. From a payer perspective, a PCV7 CIP would achieve an
ICER of RMB61, 243 (USD9, 141) per QALY versus no vaccination, and dominant
versus Category II. CONCLUSIONS: Results from this study indicate a PCV7 CIP
would be a highly cost-effective intervention from a public payer’s perspective.
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OBJECTIVES: Attention deficit/hyperactivity disorder (ADHD) is a common psychi-
atric disorder with substantial clinical and economic implications. While psycho-
stimulants are first-line pharmacologic treatment, up to 30% of ADHD children
have suboptimal response to psychostimulants and require adjunctive therapy.
Our objective was to analyze the cost-effectiveness of adding an alpha-2A agonist,
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